Form 8-K

8-K — OSR Health, Inc.

Accession: 0001213900-26-113126

Filed: 2026-10-28

Period: 2026-10-23

CIK: 0001840425

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — ea0309929-8k_osrhealth.htm (Primary)

EX-99.1 — PRESS RELEASE OF OSR HEALTH, INC., DATED OCTOBER 28, 2026 (ea030992901ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0309929-8k_osrhealth.htm · Sequence: 1

false

0001840425

2026-10-23

0001840425

OSRH:CommonStockParValue0.0001PerShareMember

2026-10-23

0001840425

OSRH:RedeemableWarrantsExercisableForSharesOfCommonStockAtExercisePriceOf11.50PerShareMember

2026-10-23

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities

Exchange Act of 1934

Date of Report (Date of earliest event reported):

October 23, 2026

OSR HEALTH, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware

001-41390

84-5052822

(State or Other Jurisdiction

(Commission File Number)

(IRS Employer

of Incorporation)

Identification No.)

10900 NE 4th Street, Suite 2300, Bellevue, WA

98004

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s telephone number, including

area code (425) 635-7700

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is

intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))

Securities registered pursuant to Section

12(b) of the Act:

Title of each class

Trading Symbol(s)

Name

of each exchange on which registered

Common stock, par value $0.0001 per share

OSRH

The Nasdaq Stock Market LLC

Redeemable warrants, exercisable for shares of common stock at an exercise price of $11.50 per share

OSRHW

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the

Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued

Listing Rule or Standard; Transfer of Listing.

As previously disclosed, trading in the common

stock and warrants of OSR Health, Inc. (the “Company”) on The Nasdaq Stock Market LLC (“Nasdaq”) was suspended

effective at the open of trading on August 26, 2026, due to the Company’s non-compliance with the minimum bid price requirement

set forth in Nasdaq Listing Rule 5550(a)(2), and the Company requested a hearing before the Nasdaq Hearings Panel (the “Panel”).

On October 23, 2026, the Company received a written

decision from the Panel denying the Company’s request for continued listing and determining to delist the Company’s securities

from Nasdaq. The Company’s securities continue to be quoted on the over-the-counter market under the symbols “OSRH”

and “OSRHW.” The Company is evaluating its options.

Item 7.01. Regulation FD Disclosure.

On October 28, 2026, the Company issued a press

release providing an update to shareholders following the Panel’s decision. A copy of the press release is furnished as Exhibit

99.1 to this Current Report on Form 8-K.

The information in this Item 7.01, including Exhibit

99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,

as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated

by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific

reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description

99.1

Press Release of OSR Health, Inc., dated October 28, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: October 28, 2026

OSR HEALTH, INC.

By:

/s/

Kuk Hyoun Hwang

Name:

Kuk Hyoun Hwang

Title:

Chief Executive Officer

EX-99.1 — PRESS RELEASE OF OSR HEALTH, INC., DATED OCTOBER 28, 2026

EX-99.1

Filename: ea030992901ex99-1.htm · Sequence: 2

Exhibit 99.1

OSR Health Provides Shareholder Update Following Nasdaq Panel Decision

Company evaluating options to regain compliance; further update

expected by November 6, 2026; $15 million VXM01 funding mechanism remains in place; committed to continuing Shareholder Loyalty Program

BELLEVUE, Wash., October 28, 2026 – OSR Health, Inc. (OTC:

OSRH) (“OSR Health” or the “Company”), a global healthcare holding company, today provided an update to shareholders

following the decision of the Nasdaq Hearings Panel to delist the Company’s securities from The Nasdaq Stock Market.

Nasdaq decision

On October 23, 2026, the Nasdaq Hearings Panel determined to delist

the Company’s securities for non-compliance with Nasdaq’s $1.00 minimum bid price requirement. The Company’s common

stock has been quoted on the over-the-counter market under the symbol “OSRH” since trading on Nasdaq was suspended on August

26, 2026. The Panel’s decision does not affect the Company’s status as an SEC-reporting company.

Throughout the compliance process, the Company chose not to pursue

a reverse stock split. The Company believed that its share price should reflect the progress of its business rather than a change in share

count, and it sought instead to regain compliance through organic value-creating initiatives.

“In our Hub-and-Spoke business structure, the listed status of the Hub matters, and we are evaluating our pathway to regaining our

listing,” said Peter Hwang, Chief Executive Officer of OSR Health. “We remain focused on advancing our pipeline, securing

our funding, and returning to a national exchange on the strength of our business.”

Path back to a national exchange

Returning to a national securities exchange remains a priority. The

Company is evaluating a range of options to regain compliance with applicable listing standards, including strategic and corporate alternatives,

and intends to provide a further update on its plan on or before November 6, 2026.

$15 million VXM01 funding mechanism

The Company’s $15 million equity put option against BCM Europe

AG under the Global Exclusive License Agreement for VXM01 remains in place. As amended on October 15, 2026, it may also be settled through

the issuance of convertible notes for an equal amount of the principal ($15 million) at fixed conversion prices of approximately $2.00

to $5.00 per share.

Shareholder Loyalty CVR Program

Reflecting its commitment to long-term shareholders, the Company intends

to seek to continue its Shareholder Loyalty CVR Program for enrolled holders, including by amending the CVR Agreement so that price thresholds

are measured on the principal market on which its common stock is then listed or quoted. Enrolled holders will be updated as this progresses.

Pipeline development continues

Development continues across the Company’s portfolio, including

VXM01, Vaximm’s oral T-cell immunotherapy, for which Vaximm is currently preparing a publication of its new data analysis on the

completed Phase 2a trial in glioblastoma; Darnatein’s regenerative protein programs, which continue to be the subject of licensing

discussions with a potential licensee; and Woori IO’s noninvasive glucose monitoring technology, with numerous parties from around

the globe having expressed an interest in potential partnerships.

“We thank our shareholders for their patience and resilience

through this process,” said Tim Smith, Head of Investor Relations at OSR Health. “Our current trading venue may have changed,

but our mission has not. We continue to build the business and pursue potential partnerships, we remain fully SEC-reporting, and we look

forward to updating shareholders by November 6 on our plan to regain a national securities exchange listing.”

About OSR Health, Inc.

OSR Health, Inc. (OTC: OSRH) is a global healthcare holding company

dedicated to advancing biomedical innovations in health and wellness. Through its subsidiaries, OSR Health engages in immuno-oncology,

regenerative biologics, and medical device technologies to improve health outcomes worldwide. Learn more at www.OSR-Health.com.

Investor Contact

OSR Health, Inc.

Investor Relations

ir@osr-health.com

Forward-Looking Statements

This press release

contains forward-looking statements, including statements regarding the Company’s evaluation of options to regain compliance with

listing standards and the timing of any further update, its plans to seek to return to a national securities exchange, the availability

of funding under its agreements with BCM Europe AG, the continuation of its Shareholder Loyalty Program, and the development of its product

candidates. These statements involve risks and uncertainties that could cause actual results to differ materially, including the outcome

of any option the Company may pursue, the Company’s ability to satisfy listing standards, the ability of BCM Europe AG or a designated

purchaser to fund its obligations, the Company’s ability to amend the CVR Agreement on acceptable terms, and the other risks described

in the Company’s SEC filings. The Company undertakes no obligation to update these statements except as required by law.

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.3

Cover

Oct. 23, 2026

Document Type

8-K

Amendment Flag

false

Document Period End Date

Oct. 23, 2026

Entity File Number

001-41390

Entity Registrant Name

OSR HEALTH, INC.

Entity Central Index Key

0001840425

Entity Tax Identification Number

84-5052822

Entity Incorporation, State or Country Code

Entity Address, Address Line One

10900 NE 4th Street

Entity Address, Address Line Two

Suite 2300

Entity Address, City or Town

Bellevue

Entity Address, State or Province

Entity Address, Postal Zip Code

98004

City Area Code

425

Local Phone Number

635-7700

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

Common stock, par value $0.0001 per share

Title of 12(b) Security

Common stock, par value $0.0001 per share

Trading Symbol

OSRH

Security Exchange Name

NASDAQ

Redeemable warrants, exercisable for shares of common stock at an exercise price of $11.50 per share

Title of 12(b) Security

Redeemable warrants, exercisable for shares of common stock at an exercise price of $11.50 per share

Trading Symbol

OSRHW

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=OSRH_CommonStockParValue0.0001PerShareMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=OSRH_RedeemableWarrantsExercisableForSharesOfCommonStockAtExercisePriceOf11.50PerShareMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type: